ERBB2 and neoplasm: For subcutaneous tumours, take rates were 100% (6/6) for the 4T1.2 tumours, 33% (1/3) for the 4T1.2-HER2 tumours, and 90% (9/10) for the 4T1.2-HER2T tumours.